» Articles » PMID: 33979642

Axenic Amastigotes of Leishmania Species As a Suitable Model for in Vitro Studies

Overview
Journal Acta Trop
Publisher Elsevier
Specialty Tropical Medicine
Date 2021 May 12
PMID 33979642
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Leishmania spp. are etiological agents of infection diseases, which in some cases can be fatal. The main forms of their biological cycle, promastigotes and amastigotes, can be maintained in vitro. While promastigotes are easier to maintain, amastigotes are more complex and can be obtained through different ways, including infection assays of tissues or in vitro cells, and differentiation from promastigotes to axenic amastigotes. Several protocols have been proposed for in vitro differentiation for at least 12 Leishmania spp. of both subgenera, Leishmania and Viannia. In this review we propose a critical summary of axenic amastigotes induction, as well as the impact of these strategies on metabolic pathways and regulatory networks analyzed by omics approaches. The parameters used by different research groups show considerable variations in temperature, pH and induction stages, as highlighted here for Leishmania (Viannia) braziliensis. Therefore, a consensus on strategies for inducing amastigogenesis is necessary to improve accuracy and even define stage-specific biomarkers. In fact, the axenic amastigote model has contributed to elucidate several aspects of the parasite cycle, however, since it does not reproduce the intracellular environment, its use requires several precautions. In addition, we present a discussion about using axenic amastigotes for drug screening, suggesting the need of a more sensitive methodology to verify cell viability in these tests. Collectively, this review explores the advantages and limitations found in studies with axenic amastigotes, done for more than 30 years, and discuss the gaps that impair their use as a suitable model for in vitro studies.

Citing Articles

Human-Validated Neural Networks for Precise Amastigote Categorization and Quantification to Accelerate Drug Discovery in Leishmaniasis.

Sorrilha-Rodrigues A, Paes J, Rizk Y, da Silva F, Rosalem R, Pinto de Arruda C ACS Omega. 2025; 10(1):1177-1187.

PMID: 39829493 PMC: 11740139. DOI: 10.1021/acsomega.4c08735.


Susceptibility of Axenic Amastigotes to the Calpain Inhibitor MDL28170.

Oliveira S, Marinho F, Sangenito L, Seabra S, Menna-Barreto R, dAvila C Trop Med Infect Dis. 2024; 9(11).

PMID: 39591265 PMC: 11598141. DOI: 10.3390/tropicalmed9110259.


Effect of the aggregated protein dye YAT2150 on parasite viability.

Roman-Alamo L, Avalos-Padilla Y, Bouzon-Arnaiz I, Iglesias V, Fernandez-Lajo J, Monteiro J Antimicrob Agents Chemother. 2024; 68(3):e0112723.

PMID: 38349159 PMC: 10916400. DOI: 10.1128/aac.01127-23.


A short-term method to evaluate anti-leishmania drugs by inhibition of stage differentiation in Leishmania mexicana using flow cytometry.

Teh-Poot C, Dzul-Huchim V, Mercado J, Villanueva-Lizama L, Bottazzi M, Jones K Exp Parasitol. 2023; 249:108519.

PMID: 37004860 PMC: 10231665. DOI: 10.1016/j.exppara.2023.108519.


Generation of Aurachin Derivatives by Whole-Cell Biotransformation and Evaluation of Their Antiprotozoal Properties.

Kruth S, Zimmermann C, Kuhr K, Hiller W, Lutz S, Pietruszka J Molecules. 2023; 28(3).

PMID: 36770729 PMC: 9919615. DOI: 10.3390/molecules28031066.